The Trump administration is proposing to ask Congress for spending cuts that include about $7 billion from the Children's Health Insurance Program; lawmakers are set to question opioid distributors about the role they may have played in the nation’s substance use disorder epidemic; the House is proposing a provision in its farm bill that would allow cheaper but less comprehensive health insurance.
The Trump Administration is proposing to ask Congress to cut $15 billion in spending, including about $7 billion from the Children's Health Insurance Program (CHIP), Reuters reported. The targeted cuts reportedly would cover money that is not being spent and would not have an effect on the CHIP program itself, an administration official said.
Lawmakers are set to question opioid distributors Tuesday during a hearing of a House Energy and Commerce subcommittee about the role they may have played in the nation’s substance use disorder epidemic. The Wall Street Journal reported that at least 1 company official—from Cardinal Health—is expected to say that his industry did have a hand in the crisis by shipping too many pills and he regrets it.
The House is proposing to include in its version of the farm bill a provision that would allow cheaper but less comprehensive health insurance than plans offered through the Affordable Care Act, Kaiser Health News reported. The plans would be similar to association-type health plans and would involve $65 million in loans and grants administered by the Department of Agriculture.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen